ow-dose buprenorphine to prevent remifentanil-induced hyperalgesia after major lung resection: a prospective, randomised, controlled, double-blinded study

Completed

• Conditions: Post-operative remifentanil-induced hyperalgesia; Skin and Connective Tissue Diseases; Disturbances of skin sensation

• Registration Number: ISRCTN91017061
• Lead Sponsor: a Sapienza University of Rome (Italy)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-12-11
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Adult patients (American Society of Anaesthesiologists [ASA] grade I - III) undergoing major lung resections
2. Aged greater than 18 years, either sex

Exclusion Criteria

1. Extremely high or low weight (less than 40 kg and greater than 100 kg)
2. Known abuse of opioid drugs
3. Patients unable to manage a patient-controlled analgesia (PCA) device

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Post-operative morphine consumption (PCA).

Secondary Outcome Measures

Name	Time	Method
1. Morphine titration at the end of the surgery<br>2. Visual Analogue Scale (VAS) at rest and during coughing at 24 and 48 hours<br>3. Hyperalgesic area at 24 and 48 hours (Quantitative Sensory Testing)<br>4. Length of post-operative hospitalisation<br>5. Incidence of post-thoracotomy pain after one month from surgery